News
Cyprotex are continually developing new products and services. The latest news on these developments is shown below.
12th April 2012 - 8th Drug Discovery Workshop - Sponsored by Cyprotex
January 12, 2012
Cyprotex Pre-Closed Trading Update
December 16, 2011
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance for a Further Two Years
|
Please view our news releases for full details of our announcements. |
 |
Events
Cyprotex attends many scientific conferences and exhibitions worldwide throughout the year. Upcoming events are listed below.
High-Content AnalysisSan Francisco, California
January 24 - 25 2012
ADMET, PK/TK, and Drug Metabolism - TrainingBrussels, Belgium
January 26 - 27 2012
7th Annual International Conference on Predictive Human Toxicity and ADME/Tox StudiesBrussels, Belgium
|
|
If you are attending an event and wish to meet to discuss your needs or areas of interest, then please contact us to arrange a meeting.
Genomic ADME - gADME™
Cyprotex's proprietary gADME™ system can alert you to genetic variations in drug metabolism, allowing for personalised doses, drug rescue and repositioning.
Learn more about gADME
In vitro Micronucleus Test
Cyprotex now offers the in vitro micronucleus test for genotoxicity assessment using an automated, high content screening method for improved detection and reliability.
Learn more about our in vitro MNT service
Drug Transporters
Cyprotex provides a full range of drug-transporter studies as recommended by the ITC white paper and EMA guidelines.
Learn more about transporters
By Dr. Katya Tsaioun, Chief Scientific Officer, Cyprotex
Wiley & Sons, March 2011
